文献速递脊柱关节炎其他结缔组织病自身炎症与 IgG4 相关病

EULAR「MHC-I 病」研究组:跨学科与跨国界识别疾病共性机制

EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders.
PubMed 文献 · Ann Rheum Dis · 2023-03-27

本文阐述「MHC-I 病」概念,指一组临床表现重叠、与 MHC-I 抗原提呈通路强遗传相关的炎症性疾病,包括脊柱关节炎、白塞病、银屑病和鸟枪弹样葡萄膜炎。文章介绍 EULAR MHC-I 病研究组,旨在联合风湿科、皮肤科、眼科临床专家与免疫学、基因组学、蛋白质组学等基础与转化研究者及患者伙伴,推动表型标准化和跨学科遗传与转化研究。

要点

  • MHC-I 病包括脊柱关节炎、白塞病、银屑病和鸟枪弹样葡萄膜炎,与特定 MHC-I 等位基因及 ERAP1、ERAP2 基因变异强相关。
  • 患者表型异质性和缺乏对 MHC-I 通路的系统研究阻碍了对其病因与治疗的认识。
  • EULAR MHC-I 病研究组优先推动疾病表型与科学命名的标准化,并提出跨学科遗传与转化研究。

核心结论

  • 需要跨学科协作研究以解答 MHC-I 病病因发病机制中的未解问题,从而改善患者治疗与预后判断。

研究设计与样本

  • EULAR MHC-I 病研究组的立场与倡议文章,联合风湿病学、皮肤病学和眼科学临床专家与免疫学、基因组学、蛋白质组学等多学科基础与转化研究者及患者伙伴。

主要发现

  • 经典 MHC-I 病如脊柱关节炎、白塞病、银屑病和鸟枪弹样葡萄膜炎与特定 MHC-I 等位基因及抗原加工氨肽酶 ERAP1 和 ERAP2 基因变异强相关,提示 MHC-I 肽提呈给 CD8+T 细胞改变参与发病。
  • 患者表型异质性和缺乏对 MHC-I 通路的系统研究阻碍了对其病因和治疗的认识进展。
  • 对 MHC-I 病生物学的新认识强烈支持开展疾病跨领域及整合的分子与临床研究以阐明潜在疾病机制。

关键数值与推荐

  • 优先推动疾病表型与科学命名的标准化。
  • 提出跨学科遗传与转化研究,以利用新兴治疗策略理解 MHC-I 介导的疾病机制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 'MHC-I (major histocompatibility complex class I)-opathy' concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet's disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis. Progress in understanding the cause and treatment of these disorders is hampered by patient phenotypic heterogeneity and lack of systematic investigation of the MHC-I pathway.Here, we discuss new insights into the biology of MHC-I-opathies that strongly advocate for disease-overarching and integrated molecular and clinical investigation to decipher underlying disease mechanisms. Because this requires transformative multidisciplinary collaboration, we introduce the EULAR study group on MHC-I-opathies to unite clinical expertise in rheumatology, dermatology and ophthalmology, with fundamental and translational researchers from multiple disciplines such as immunology, genomics and proteomics, alongside patient partners. We prioritise standardisation of disease phenotypes and scientific nomenclature and propose interdisciplinary genetic and translational studies to exploit emerging therapeutic strategies to understand MHC-I-mediated disease mechanisms. These collaborative efforts are required to address outstanding questions in the etiopathogenesis of MHC-I-opathies towards improving patient treatment and prognostication.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kuiper JJ, Prinz JC, Stratikos E, et al. EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders. Ann Rheum Dis. 2023. PMID: 36987655. doi:10.1136/ard-2022-222852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。